BenzingaOctober 5, 2026 at 7:53 AM NY22 Days Ago
FDA Recommends Meeting for Rezolute Drug for Rare Blood Sugar Disorder Despite Missed Endpoints
Rezolute (NASDAQ: RZLT) shares surged after the FDA recommended a pre-BLA meeting for its congenital hyperinsulinism drug, ersodetug.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
